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Dispersion and release of embelin from electrospun,
biodegradable, polymeric membranes
Pablo R Cortez Tornello1,2, Gabriela E Feresin2, Alejandro Tapia2, Itiara G Veiga3, Aˆngela M Moraes3,
Gustavo A Abraham1 and Teresita R Cuadrado1
In this work, microfiber meshes containing embelin, a poorly water-soluble bioactive agent, were prepared by solubilizing
embelin in a biodegradable and biocompatible polymer matrix of poly(e-caprolactone) (PCL). Plain or drug-loaded, highly
porous, fibrous membranes with a high area-to-volume ratio were obtained by electrospinning. Non-woven microfibrous meshes
were formed by uniform bead-free fibers with a mean diameter of 1.2 lm. Non-porous films were obtained by solution casting,
and were used for comparison. The drug-loading content of the prepared systems was appropriate for topical applications. The
thermal properties revealed that the crystallinity of embelin significantly decreased, the drug having almost completely
dissolved in the PCL fibers. The in situ bioavailability of embelin, an antimycotic agent, is an important aspect to consider in
topical drug applications. The drug-loaded systems presented different contact areas with the biological environment. When
comparing the ability to expose embelin with the biological environment of the prepared systems, drug-loaded fibrous scaffolds
showed a higher bioavailability of the bioactive agent because of an increase by 86% in the area-to-volume ratio, providing
an effective area per unit mass that was 5.8-fold higher than that of the film. For the meshes, 90% embelin release was
observed after 12h of exposure to phosphate-buffered saline, whereas for the films a comparable level of release occurred
only after 72 h.
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INTRODUCTION
There is a great deal of interest in designing devices to increase the
bioavailability of poorly water-soluble drugs, which have a proven
pharmacological activity for the treatment of several skin diseases. To
achieve therapeutically important concentrations and to be optimally
bioavailable to the skin, a drug must be in solution and in a non-
ionized state. In the case of topical delivery of poorly water-soluble or
water-insoluble drugs, the solubilization of the drug in a matrix may
be considered through the use of solid solution/dispersion technol-
ogies.1,2 Although this technique is in its infancy with regard to
pharmaceutical applications, a number of publications have suggested
that the technique might be of a high value in topical drug
administration and wound healing.3,4
The use of polymer-based, electrospun micro/nanofibers contain-
ing dispersions of poorly water-soluble pharmaceuticals has been
reported for potential use in oral and topical drug delivery.3 Micro/
nanofibrous meshes have highly attractive functional characteristics,
such as high surface area-to-volume ratios, a porous structure and
biomimetic features. Because of these properties, non-woven
materials offer interesting advantages for designing drug delivery
systems.5–8 The high surface area of both the drug and the polymer
carrier increases the dissolution rate of a particulate drug, and aids in
mass transfer and efficient drug release. Depending on the polymer
carrier and its geometry, the release kinetics from a pharmaceutical
dosage form can be designed for rapid, immediate, delayed or
modified dissolution.
Processing of polymer nanofibers through electrospinning has
gained much attention in the last decade owing to its versatility for
producing a wide variety of polymeric fibers and its ability to produce
fibers in the submicron range, which is otherwise difficult to achieve
with conventional, fiber-spinning technologies.6,9,10 To form micro/
nanofibers, a stream of a polymer solution or melt is subjected to
a high electric field, forming a suspended droplet at the tip of a
nozzle. The polymer jet is initiated when the electrostatic charge
overcomes the surface tension of the droplet. Micro/nanofibers form
when the ejection jet stream is narrowed under increasing surface
charge density caused by solvent evaporation. A grounded target is
used to collect the fibers, forming a non-woven mat. In the case of
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drug-loaded systems, the drug can be incorporated along with the
polymeric solution to be electrospun. Fast and efficient solvent
evaporation provides a limited time for the drug to recrystallize,
which favors the formation of amorphous dispersions or solid
solutions.4 Moreover, electrospinning affords great flexibility in
selecting materials (for example, degradable or non-degradable
polymers, synthetic or natural polymers and composites), bioactive
agents and drugs for drug-delivery applications.5
In this work, polymeric films and electrospun, microfibrous meshes
of poly(e-caprolactone) (PCL) containing embelin, a poorly water-
soluble bioactive agent, were prepared and characterized. PCL is a
biocompatible, linear, aliphatic polyester with a glass transition
temperature of 60 1C and a melting temperature between 59 and
64 1C. Owing to its hydrophobic character and semicrystalline struc-
ture, PCL exhibits a long degradation time under physiological
conditions, on the order of 2 years. This is an attractive property that
is attractive for long-term applications in drug delivery.11 PCL degrades
by hydrolysis, and the speed of this process depends on the shape and
size of devices, on the bioactive agents dispersed in the polymer and on
the physiological characteristics of the biological environment.
Embelin is a natural benzoquinone isolated as the main secondary
metabolite from species of the Myrsinaceae12,13 and Oxalidaceae14
families. Embelin shows a diversity of relevant biological activities,
such as a chemopreventive effect against N-nitrosodiethylamin/
phenobarbital (DENA/PB)-induced hepatocarcinogenesis in Wistar
rats,15 anti-fertility effects,16 in vitro cytotoxic activity against B16 and
XC cell lines,17 and anticonvulsant,18 antidiabetic19 and antimicrobial
activities.14 Patel et al.20 studied the formulation of embelin tablets
containing different diluents and employing wet granulation and
direct compression techniques. To the best of our knowledge, the
incorporation of embelin into polymeric matrices without using
diluents has not been previously reported in the literature. The
prepared embelin-based systems, including polymeric films and
microfibrous meshes, were characterized in terms of drug content,
thermal properties and morphology.
EXPERIMENTAL PROCEDURE
Materials
Embelin (2,5-dihydroxy-3-undecil-1,4-benzoquinone) was obtained from
Oxalis erythrorhiza Gillies ex Hooker et Arnott (Oxalidaceae)12,21 collected in
the province of San Juan, Argentina, following the procedure described by
Feresin et al.14 Figure 1 shows the chemical structure of embelin. Its empirical
formula is C17H26O4, and its molecular weight is 294.39 gmol
1. Embelin
consists of a yellow-orange compound that crystallizes in the form of golden
yellow needles. It is poorly soluble in water but highly soluble in solvents such
as dichloromethane, methanol, petroleum ether and chloroform. PCL, with a
number-average molecular weight of 80 kgmol1, dichloromethane and
methanol were obtained from Aldrich Chemical Co. (St Louis, MO, USA)
and used without further purification.
Films and microfibrous meshes preparation
PCL solutions (10wt %) were prepared by dissolving PCL pellets in a
dichloromethane:methanol solvent mixture (50:50 by volume) under magnetic
stirring. For the preparation of drug-loaded films and meshes, 5 and 18wt %
of embelin with respect to PCL were added to the polymeric solution,
respectively. These amounts of drug were selected to assure the minimum
inhibitory concentration index of embelin in each type of sample. Feresin
et al.14 reported that embelin was active against Trypanosoma cruzi
trypomastigotes at a minimum inhibitory concentration of 100mgml1.
Recently, Radhakrishnan et al.22 reported the bactericidal activity of embelin
against Gram-positive organisms and bacteriostatic against Gram-negative
organisms, with a minimum inhibitory concentration value o100mgml1.
On the basis of that report, the prepared samples contained a sufficient
amount of drug to act as effective drug-carrier systems for both bactericidal
and trypanocidal activity. The flask in which the precursors were mixed was
protected from light during the dissolution process, and a mixture was
maintained under magnetic stirring at room temperature. The amount of
embelin to be loaded was estimated by considering the amount required to
prepare non-porous and porous discs containing 100mg of embelin.
Films were prepared by solution casting (5ml) onto a petridish (4.6mm in
diameter). Drying was carried out under a fume hood at room temperature for
24h. Samples were subsequently vacuum dried to remove residual solvent.
Electrospun microfibrous meshes were obtained by electrospinning. Each of the
as-prepared solutions was loaded into a standard 10-ml plastic syringe connected
to a polyamide tube attached to the open end of a blunt, 18-gauge, stainless steel
hypodermic needle used as a nozzle. The flow rate was controlled with a
programmable syringe pump (Activa A22 ADOX S.A., Ituzaingo´, Argentina). A
high-voltage power source (ES30P, Gamma High Voltage Research Inc., Ormond
Beach, FL, USA) was used to charge the solution by attaching the emitting
electrode of positive polarity to the nozzle and the grounding electrode to the
aluminum-collecting plate. All experiments were carried out at room temperature
in a chamber having a ventilation system. The solutions (typically 5ml) were
electrospun at a positive high voltage of 17kV, with a distance between the needle
tip and the collecting plate of 12 cm and a solution-feeding rate of 0.6mlh1.
The electrospun scaffolds were dried under vacuum at room temperature to fully
eliminate the residual solvent and were stored in a desiccator.
Disc samples (3mm in diameter) were cut and named PCLf and PCLm,
denoting the PCL films and PCL meshes, respectively, whereas the drug-loaded
materials were referred to as PCLEf and PCLEm for embelin-loaded PCLf and
PCLm, respectively.
Polymer and drug characterization
Embelin content was determined by ultraviolet-visible spectroscopy (Agilent
8453, Santa Clara, CA, USA). Discs were dissolved in dichloromethane:metha-
nol (50:50 by volume), and quantification was carried out after calibration,
observing the absorption band at l¼ 305 nm. The loading efficiency was
calculated from the ratio between the final and the initial embelin-to-polymer
mass ratios. The thermal properties of PCL, embelin and embelin-loaded
systems were determined by differential scanning calorimetry (Perkin Elmer
Pyris 1, Waltham, MA, USA). Scans were performed at a heating rate of
5 1Cmin1. Thermograms were obtained under nitrogen purge. The degree of
crystallinity of PCL (Xc) was calculated taking 148.05 J g
1 as the melting heat
for pure high-molecular-weight PCL.23 The morphologies of the films and
electrospun scaffolds were examined by scanning electron microscopy (JEOL
JSM6460 LV, Peabody, MA, USA) after gold sputtering. The mean fiber
diameter and diameter distribution were obtained with an image analyzer
(Image-Pro Plus, Media Cybernetics, Inc., Bethesda, MD, USA).
Embelin release measurements
PCLEf and PCLEm release behaviors (10 discs of 10mm in diameter) were
measured in glass flasks containing 200ml of phosphate-buffered saline at
pH¼ 7.4 and 37 1C. Stirring was performed with an orbital shaker at
150 r.p.m.. Samples of 1ml were taken from the dissolution medium each
1 h during the first 12h, and one sample per day was taken during 18 days. A
total of 30 extractions were performed. After each extraction, 1ml of fresh
solvent was added. The total volume extracted was o15% of the solution
volume. All the assays were performed in triplicate. The concentration of
embelin was determined by ultraviolet–visible spectroscopy (Agilent 8453)
observing the absorption band at l¼ 305 nm. The percentage of embelin
O
O
OH
CH3HO
Figure 1 Chemical structure of embelin (2,5-dihydroxy-3-undecil-1,4-
benzoquinone).
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released was calculated by dividing the accumulated amount of embelin
released at each sampling time by the initial amount of embelin (mEmb).
RESULTS AND DISCUSSION
Characterization of films and microfibrous meshes
In electrospinning, the diameter and morphology of the produced
micro/nanofibers are governed by a number of factors, including the
solution parameters (solution dielectric constant, conductivity, poly-
mer type and concentration and surface tension), the processing
parameters (flow rate of the solution, applied voltage and needle tip-
to-collector distance) and the environmental parameters (temperature
and humidity).24 The spinning conditions used in this work were
selected based on a series of screening experiments to avoid
electrospraying of the solution. Thus, the experimental parameters
that were established led to the production of uniform and
continuous fibers.
To study the surface morphology of electrospun meshes and films,
the surfaces of the samples in contact with air, aluminum foil and
glass were observed by scanning electron microscopy. No significant
differences were found in the surfaces contacting air and either
aluminum foil or glass. The typical appearance of the films and
meshes obtained are shown in Figures 2–5.
The surface of PCLf appeared to be smooth without visible pores,
whereas PCLm displayed a typical electrospun structure of random
microfibers (Figures 2 and 4). The mesh exhibited a very high surface
area-to-volume ratio, high porosity and an interconnected pore
structure. PCLm samples exhibited uniform bead-free fibers. Accord-
ing to a digital image-processing technique recently proposed by
Gonzalez et al.25 that allows the characterization of different
morphological characteristics of electrospun scaffolds from scanning
electron micrographs, the mean diameter of the fibers and their size
distribution were determined. Figure 6 shows the fiber-diameter
frequency distribution. The average fiber diameters were
1.267±0.576mm for PCLm and 1.286±0.667mm for PCLEm, which
indicates that the amount of embelin incorporated in the polymeric
solution did not cause a significant change in the mean fiber diameter
and morphology.
As shown in Figure 3, PCLEf micrographs reveal needle-like
structures that can be ascribed to the presence of a small fraction
of crystallized embelin. The same feature is observed in the PCLEm
Figure 2 Scanning electron micrograph of PCLf (surface exposed to air;
5000).
Figure 3 Scanning electron micrograph of PCLEf (surface exposed to air;
5000).
Figure 4 Scanning electron micrograph of PCLm (surface exposed to air;
3000).
Figure 5 Scanning electron micrograph of PCLEm (surface exposed to air;
3000).
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micrographs (Figure 5). In both cases, the presence of partially
crystallized embelin was confirmed later by thermal analysis.
Although, in the film, much of the needle-like structures are found
at the surface, this morphological feature cannot be directly related to
the crystallinity of the samples. In the solution-cast film, the
distribution of crystals through the film thickness is not necessarily
uniform. However, in the electrospun mesh, the microfibrous
structure allowed a better distribution of embelin and its crystalline
phase throughout the material.
To study the availability of bioactive agent in microfibrous
materials exposed to biological media, the evaluation of device size
and geometrical parameters is required. The morphological analysis
commonly found in the literature is very simplified and does not take
into account the real morphology of the scaffold. A detailed
description that includes the device structural aspects is necessary
to understand the behavior of drug-loaded, fibrous biomaterials. For
this purpose, the effective area was calculated considering the image
analysis data. First, the area Ai occupied by fibers of a given diameter
Di was calculated as follows:
Ai¼ fi  p2i
 
/4; ð1Þ
where, fi is the fraction of fibers with a given diameter Di, according
to data displayed in Figure 6. The mass occupied by fibers having Di
per unit length, Mi, considering the polymer density (r) is
Mi¼Ai  r; ð2Þ
and the effective length of the fibers with diameter Di per gram of
sample, Li is
Li¼ 1/Mi: ð3Þ
Then, the total effective area per gram of sample Ame, the total
effective area per unit volume Ave and the total effective area AT
considering both sides of each, were calculated as follows:
Ame¼
X
Ami¼
X
Li  p  Dið Þ; ð4Þ
Ave¼Ame  r; ð5Þ
AT ¼Ave  V ; ð6Þ
where, V is the disc volume. Table 1 summarizes the calculated values.
These results indicate that PCLEm samples have a total effective area
1.67-fold higher than that of the PCLEf discs. Therefore, the
morphology of this microfibrous membrane containing highly dis-
persed embelin assures the higher exposure of embelin to the
biological environment. PCLEm discs also exhibited an increase of
86% in the effective area-to-volume ratio. Thus, the exposure of
embelin could be improved in the PCLEm device when compared
with PCLEf because of the fact that the mesh showed a 5.8-fold
increase in the effective area per unit mass.
Embelin quantification
The embelin content, in terms of the total mass of embelin per disc
(mEmbT) and the mass of embelin per unit mass of sample (mEmb), as
determined by ultraviolet-visible spectroscopy, is shown in Table 2.
The obtained data indicate that the loading efficiency of embelin in
PCLEm discs was 83%, whereas in the case of PCLEf discs, the loading
efficiency was 98%. The lower loading efficiency of embelin in the
microfibrous meshes can be attributed to electrospinning. During the
electrospinning process, the solvent evaporation that occurs in
the needle causes the removal of a small amount of embelin that
remains attached to the tip, thereby decreasing the amount incorpo-
rated in the resulting fibers. The active compound content of the
prepared systems is sufficient for the proposed applications.
Embelin release studies
The release profiles of embelin from PCLEf and PCLEm samples are
shown in Figure 7. The results show that despite the poor water
solubility of embelin, it is released from the hydrophobic PCL matrix
into the aqueous solution. Two different stages are seen in the release
profile, namely a rapid loss of embelin deposited on the surface of
the devices followed by a slow-release phase, probably involving the
diffusion of the active agent molecules through the PCL matrix to
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Figure 6 Diameter frequency distribution of electrospun fibers: (a) PCLm; n¼100; diameter: 1.267±0.576mm; (b) PCLEm; n¼100; diameter:
1.286±0.667mm.
Table 1 Effective areas Ame, Ave and AT estimated for PCLf and
PCLEm discs
Sample Ame (cm
2 g1) Ave (cm1) AT (cm2)
PCLEf 111.45 41.89 0.21
PCLEm 645.37 78.09 0.35
Abbreviations: Ame, total effective area per gram of sample; AT, total effective area; Ave, total
effective area per unit volume; PCLf, poly(e-caprolactone) films; PCLEf, embelin-loaded
poly(e-caprolactone) films; PCLEm, embelin-loaded poly(e-caprolactone) meshes.
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the aqueous solution. The initial burst release observed in both
samples lasted B10h. However, whereas for the meshes, 80% of the
embelin was already released B8 h after exposure to phosphate-
buffered saline (PBS), for the films this percentage was reached only
after 24 h. Longer periods were required to attain full release, possibly
due to the interaction of embelin and PCL. Although the amount of
embelin per disc is higher in the films, the mesh had a higher
percentage of released embelin owing to its higher effective surface
area.
Both types of devices can be considered thin films because of their
low thickness values (0.063 cm for the mesh and 0.070 cm for the
film) when compared with their diameters (equal to 1 cm). Addi-
tionally, given that the solubility limit of embelin in PBS at pH 7.4 is
0.13mgml1, according to Patel et al.,20 it can be assumed that the
equilibrium between embelin and the buffer was not reached in either
of the tested cases, as the maximum released concentration did not
exceed 4% of the maximum solubility. Therefore, both tested systems
remained under sink conditions during the entire period of drug-
release evaluation.
In the present study, the devices in the form of films and meshes
can probably both be considered monolithic dispersions because part
of the embelin is homogeneously distributed within the PCL matrix at
an initial concentration greater than drug solubility. Upon contact
with PBS, the solution penetrates into the system and only partially
dissolves the drug. As a consequence, dissolved and non-dissolved
embelin coexist within the matrix during drug release. Polymer
degradation cannot be considered a reason to justify improved drug
transport in both types of PCL devices because this polymer has a
relatively long hydrolytic degradation time.
Different types of mathematical models are available in the
literature to describe the release behavior of drugs incorporated into
polymeric devices, as reviewed by Siepmann and Siepmann.26 In the
simplest case, known as the zero-order release model, the release rate
remains constant until the active compound is exhausted in the
matrix. If the entire release study period is considered, this is clearly
not the behavior observed in any of the evaluated PCL–embelin
systems, but this model describes the data from the initial release
period for both sets of data reasonably well, probably because of the
predominant solid-drug dissolution at this stage.
Another model frequently used and easy to apply is the Peppas
equation:
Mt
M1
¼ ktn; ð7Þ
where, Mt and MN are the cumulative amounts of drug released at
time t and infinite time, respectively, k is a constant related to the
structural and geometric characteristics of the delivery device and n is
the release exponent, which might be indicative of the mechanism of
drug release. For thin films, n is equal to 0.5 when Fickian diffusion
applies and 1.0 for polymer swelling situations, attaining values
between 0.5 and 1.0 in the case of anomalous transport. These models
are normally useful for an Mt/MN ratio lower than 0.6.
When this model was tested to adjust the obtained experimental
data in the region of Mt/MN o0.6, values of R2 equal to 0.997 and
0.992 and of n equal to 0.85 and 1.14 were determined for the mesh
and the film devices, respectively. In the case of the mesh, the
superposition of apparently independent mechanisms of drug trans-
port might occur. In all likelihood, this result should be attributed to
the rapid dissolution of the solid embelin deposited on the surface of
the materials rather than to swelling of the polymer matrix because
the PBS absorption by PCL in 10h was found to be o0.5%.
For the film, in addition to the convective transport associated with
the dissolution of the solid embelin accumulated at the device surface,
because n41, a super-case II transport may be considered, as for
instance, a result of void formation in the matrix.27 Voids might have
formed during casting by rapid volatilization of the solvent within the
film, resulting in an increased film surface area and serving as a
pathway for the solvent to diffuse through the film. In addition,
during embelin release, the dissolution of the active compound might
have produced cavities in the PCL matrices, as observed for the
antibacterial nalidixic acid incorporated in PCL matrices blended with
other biodegradable synthetic polymers.28 According to Douglas
et al.,28 when the percentage of active agent incorporated into the
polymer matrix is between 5 and 10%, the release mechanism is
indeed more complex because the pores resulting from the cumulative
exit of the active agent formerly deposited on the surface are filled by
the liquid medium, thereby facilitating the release of the compound
still incorporated in the polymer matrix. In this situation, as the
percentage of incorporated material is relatively low, the pores are
frequently not interconnected, but increases in matrix permeability
are observed, facilitating drug transport through the system. At higher
active agent ratios, the connection of pores might occur, further
increasing the permeability of the system.
Thermal properties
The thermal transitions of free embelin, PCLf, PCLm, PCLEf and
PCLEm, were determined by differential scanning calorimetry. The
obtained thermograms are shown in Figure 8, whereas the melting
temperature (Tm), the melting heat (DHm) and degree of crystallinity
(Xc) are summarized in Table 3.
As expected, the solution-cast film PCLf displayed a higher
crystallinity (49.1%) compared with the corresponding electrospun
Figure 7 Release profiles of embelin from PCLEf and PCLEm samples
in PBS at pH¼7.4 and 37 1C.
Table 2 Embelin quantification by ultraviolet-visible spectroscopy
Sample
mEmbT (mg embelin
per disc)
mEmb (mg embelin
per g of sample)
Film 93.70 46.85
Mesh 65.07 130.15
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mesh PCLm (35.8%). The same observation for PCL nanofibrous
meshes was performed by Lee et al.29 after analyzing wide angle X-ray
diffraction patterns. Structure formation during electrospinning is
governed by the simultaneous processes of solvent evaporation and
elongation of the solidifying fiber. In semicrystalline polymers,
solidification is also concurrent with crystal nucleation. The shorter
time for crystallization is expected to limit the development of
crystallinity, resulting in small crystallites with defects and thus a
lower degree of crystallinity.30 In the case of PCL, the crystallization
process could not be completely suppressed.
In the case of drug-loaded samples, the crystallinity of PCL also
decreased in the electrospun samples, probably facilitating drug
transport within the matrix after exposure to PBS. Embelin displayed
three well-defined melting peaks. However, these melting signals are
almost completely absent in the embelin-loaded samples PCLEf and
PCLEm (see insert in Figure 8). Embelin showed a strong reduction in
the degree of crystallinity (from 100 to 4.7% in the film and 13% in
the mesh), indicating a marked solubilization of embelin in the PCL
matrix. The crystallization of embelin not only could not be fully
circumvented but also showed an opposite behavior in comparison
with the polymer, increasing more in the electrospun samples. From
these results, it is clear that the electrospinning process affects the
polymer and the drug in different ways. This behavior can be
explained by the different structure and chain length of these species
that could allow the formation of a small fraction of embelin crystals
during jet formation. The polymer carrier stabilized the formed
amorphous drug dispersion/solution through vitrification or via
specific molecular interactions, with the tendency for the drug to
recrystallize being suppressed or at least made kinetically unfavorable
for a long enough period to make the material pharmaceutically
useful.31
CONCLUSIONS
Poly(e-caprolactone) matrices containing embelin were successfully
obtained by solution casting and electrospinning. The bioactive agent
was significantly dissolved in the polymeric matrices, as shown by the
thermal analysis. Microfibrous, embelin-loaded PCL meshes exhibited
a significant decrease in drug crystallinity, indicating good solubiliza-
tion in the polymer matrix. Moreover, the improved capacity of the
meshes to expose amorphous embelin as well as the higher surface
area-to-volume and mass-to-volume ratio make the porous scaffolds
appropriate for preparing drug-loaded, polymeric matrices with
improved efficiency if a relatively high drug-release rate is desired.
The in vitro and in vivo antifungal efficiencies of embelin-loaded
meshes against dermatophytes, such as Trichophyton mentagrophytes,
are currently under investigation.
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